BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18279371)

  • 1. The genetic differences with whole genome linkage disequilibrium mapping between responder and non-responder in interferon-alpha and ribavirin combined therapy for chronic hepatitis C patients.
    Chen PJ; Hwang Y; Lin CG; Wu YJ; Wu LS
    Int J Immunogenet; 2008 Apr; 35(2):153-7. PubMed ID: 18279371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
    Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
    World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
    Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
    Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin.
    Sadeghi S; Davari M; Asli E; Gharibzadeh S; Vaziri F; Jamnani FR; Fateh A; Siadat SD
    Gene; 2017 Sep; 630():28-34. PubMed ID: 28827115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
    Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
    J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.
    Fernández-Rodríguez A; Jiménez-Sousa MÁ; Resino S
    Gene; 2013 Jun; 522(1):121. PubMed ID: 23506831
    [No Abstract]   [Full Text] [Related]  

  • 8. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Tanaka Y; Nishida N; Sugiyama M; Kurosaki M; Matsuura K; Sakamoto N; Nakagawa M; Korenaga M; Hino K; Hige S; Ito Y; Mita E; Tanaka E; Mochida S; Murawaki Y; Honda M; Sakai A; Hiasa Y; Nishiguchi S; Koike A; Sakaida I; Imamura M; Ito K; Yano K; Masaki N; Sugauchi F; Izumi N; Tokunaga K; Mizokami M
    Nat Genet; 2009 Oct; 41(10):1105-9. PubMed ID: 19749757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
    World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Shi KQ; Liu WY; Lin XF; Fan YC; Chen YP; Zheng MH
    Gene; 2012 Oct; 507(1):27-35. PubMed ID: 22842190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients.
    Zhang YY; Chen HB; Xu Y; Huang P; Wang J; Zhang Y; Yu RB; Su J
    World J Gastroenterol; 2015 Apr; 21(13):4006-13. PubMed ID: 25852288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.
    Heidari Z; Shahzamani K; Ghanbari R; Tahamsebifar A
    Acta Med Iran; 2014; 52(10):740-7. PubMed ID: 25369007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of vitamin D pathway predict antiviral treatment outcome in slow responder naïve patients with chronic hepatitis C.
    Falleti E; Cmet S; Fabris C; Fattovich G; Cussigh A; Bitetto D; Ceriani E; Lenisa I; Dissegna D; Ieluzzi D; Rostello A; Pirisi M; Toniutto P
    PLoS One; 2013; 8(11):e80764. PubMed ID: 24244713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.
    Yuan H; Adams-Huet B; Petersen T; Attar N; Lee WM; Jain MK
    J Med Virol; 2012 Dec; 84(12):1913-9. PubMed ID: 23080496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 27 polymorphisms in HCV RNA positive patients: is there an impact on response to interferon therapy?
    Zicca E; Quirino A; Marascio N; Nucara S; Fabiani F; Trapasso F; Perrotti N; Strazzulla A; Torti C; Liberto MC; Focà A
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S5. PubMed ID: 25236666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.